Originalkatalog | Verfügbarkeit prüfen

Sabatolimab ( MBG453) model‐informed drug development for dose selection in patients with myelodysplastic syndrome/acute myeloid leukemia and solid tumors

Xu, Siyan, Zhang, Na, Rinne, Mikael L., Sun, Haiying, Stein, Andrew M.
Veröffentlicht in: CPT: Pharmacometrics & Systems Pharmacology ; volume 12, issue 11, page 1653-1665 ; ISSN 2163-8306 2163-8306;
2023

Originalkatalog | Verfügbarkeit prüfen

Phase I/Ib clinical trial of Sabatolimab, an Anti-TIM-3 Antibody, Alone and in Combination With Spartalizumab, an Anti-PD-1 Antibody, in Advanced Solid Tumors

Curigliano, Giuseppe, Gelderblom, Hans, Mach, Nicolas, Doi, Toshihiko, Tai, Wai Meng, Forde, Patrick M, Sarantopoulos, John, Bedard, Philippe L, Lin, Chia-Chi, Hodi, F Stephen, Wilgenhof, Sofie, Santoro, Armando, Sabatos-Peyton, Catherine, Longmire, Tyler A, Xyrafas, Alexandros, Sun, Haiying, Gutzwiller, Sabine, Manenti, Luigi, Naing, Aung
2021

Originalkatalog | Verfügbarkeit prüfen

Phase Ib study of sabatolimab (MBG453), a novel immunotherapy targeting TIM-3 antibody, in combination with decitabine or azacitidine in high- or very high-risk myelodysplastic syn...

Brunner, Andrew M., Esteve, Jordi, Porkka, Kimmo, Knapper, Steve, Traer, Elie, Scholl, Sebastian, Garcia-Manero, Guillermo, Vey, Norbert, Wermke, Martin, Janssen, Jeroen J. W. M., Narayan, Rupa, Fleming, Shaun, Loo, Sun, Tovar, Natalia, Kontro, Mika, Ottmann, Oliver G., Naidu, Purushotham, Sun, Haiying, Han, May, White, Roisin, Zhang, Na, Mohammed, Anisa, Sabatos-Peyton, Catherine A., Steensma, David P., Rinne, Mikael L., Borate, Uma M., Wei, Andrew H.
Veröffentlicht in: Brunner , A M , Esteve , J , Porkka , K , Knapper , S , Traer , E , Scholl , S , Garcia-Manero , G , Vey , N , Wermke , M , Janssen , J J W M , Narayan , R , Fleming , S , Loo , S , Tovar , N , Kontro , M , Ottmann , O G , Naidu , P , Sun , H , Han , M , White , R , Zhang , N , Mohammed , A , Sabatos-Peyton , C A , Steensma , D P , Rinne , M L , Borate , U M & Wei , A H 2023 , ' Phase Ib study of sabatolimab (MBG453), a novel immunotherapy targeting TIM-3 antibody, in combination with decitabine or azacitidine in high- or very high-risk myelodysplastic syndromes ' , American Journal of Hematology . https://doi.org/10.1002/ajh.27161;
2023